Table 3.
Sample | DPPH radicala |
ABTS radicala |
Hydroxyl radicala |
Lipoproteina | SOD-like activitya (%) at 0.1 mg/mL | SOD-like activitya (%) at 0.2 mg/mL |
---|---|---|---|---|---|---|
IC50
b
(mg/mL) |
IC50
b
(mg/mL) |
IC50
b
(mg/mL) |
IC50
b
(mg/mL) |
|||
CE | 0.093 ± 0.007** | 0.43 ± 0.04** | 2.08 ± 0.08** | 0.085 ± 0.007* | 49.33 ± 0.93* | 54.92 ± 0.63** |
EAE | 0.032 ± 0.002** | 0.35 ± 0.03** | 7.20 ± 0.18** | 0.065 ± 0.001** | 60.00 ± 0.78** | 65.27 ± 0.39** |
BAE | 0.131 ± 0.020** | 0.64 ± 0.10** | — | 0.353 ± 0.024** | 54.22 ± 0.39** | 59.94 ± 0.54** |
AF | 0.213 ± 0.030** | 0.74 ± 0.04** | 2.06 ± 0.20** | 0.815 ± 0.065** | 47.43 ± 0.97 | 54.09 ± 1.02** |
BHT | 0.067 ± 0.004 | 0.091 ± 0.008 | — | — | 45.72 ± 2.19 | 47.05 ± 2.35 |
VE/AA | — | — | 0.095 ± 0.003 | 0.114 ± 0.016c | 96.24 ± 0.86c∗∗ | 99.11 ± 0.32c∗∗ |
aEach value is expressed as mean ± standard deviation (n = 3).
bIC50 (mg/mL): the concentration at which 50% is inhibited.
cVE as the control.
∗ P < 0.05; ∗∗P < 0.01 compared with BHT.